Huma aquires Alcedis to form clinical trials division

Health tech company Huma Therapeutics is to form an advanced clinical trials division following the acquisition of Alcedis GmbH.

The new division with offer digital solutions across the entire development pipeline, from early stage through to Phase IV hybrid and fully decentralised trials.

Huma’s modular platforms are used by more than 3,000 hospitals and clinics, with more than 1.8 million active users 650,000+ participants.

The company helps the health service to provide ‘hospitals at home’.

Huma CEO and founder, Dan Vahdat, said:

“Huma has been a leader in digital-first care and research, partnering with health systems and pharma companies and now with this acquisition we’re set to redefine the clinical trials sector.”

Headquartered in Giessen, Germany, Alcedis has more than 25 years of clinical trial experience.

The clinical trials company coordinates studies from the initial concept to the delivery of final results.

Alcedis managing director, Hanno Härtlein, said:

“We are excited to be joining the Huma family, bringing our clinical trials expertise and capabilities to combine with those of Huma’s award-winning technology-platform.

“Together, we will offer substantially greater benefit to pharmaceutical, medtech, clinical research organisation, and academic partners for their research projects.”

Jeanne Kehren, Senior Vice President, Digital & Commercial Innovation & Chief Information Officer, Bayer AG, added:

“The combined company will offer a one-stop shop for remote access, data, logistics and execution with advanced digital technology shaping a new clinical research ecosystem.”